Wednesday, 14 October 2026European Markets

AVENIR TELECOM Stock Went Down By Over 32% In The Last 21 Sessions

Loading stream...

(vianews) - shares of avenir telecom (cac 40: avt.pa) slid by a staggering 32.08% in 21 sessions from €0.27 to €0.18 at 05:38 est on friday, after two successive sessions in a row of gains. cac 40 is jumping 0.64% to €7,446.89, following the last session's upward trend.

about avenir telecom

avenir telecom s.a. designs and distributes mobile phones and mobility accessories in europe, the middle east, africa, asia, oceania, and the americas. the company also provides chargers, cables, memory cards, and screen protectors. it offers its products under the energizer brand. the company was incorporated in 1989 and is headquartered in marseille, france.

earnings per share

as for profitability, avenir telecom has a trailing twelve months eps of €166.34.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, avenir telecom's stock is considered to be overbought (>=80).

volume

today's last reported volume for avenir telecom is 386010 which is 88.83% below its average volume of 3730660.

volatility

avenir telecom's last week, last month's, and last quarter's current intraday variation average was a negative 4.46%, a negative 2.37%, and a positive 8.70%.

avenir telecom's highest amplitude of average volatility was 5.16% (last week), 8.26% (last month), and 8.70% (last quarter).

more news about avenir telecom (avt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com